Current Report Filing (8-k)
December 16 2022 - 8:07AM
Edgar (US Regulatory)
0001571934
false
0001571934
2022-12-16
2022-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2022
Synaptogenix, Inc.
(Exact
name of registrant as
specified in its
charter)
Delaware |
001-40458 |
46-1585656 |
(State
or other
jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
1185 Avenue of the Americas, 3rd Floor |
|
New York, New York |
10036 |
(Address of
principal executive offices) |
(zip code) |
Registrant’s Telephone Number, Including
Area Code: (973) 242-0005
Not applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, $0.0001 par value per share |
|
SNPX |
|
The Nasdaq
Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR § 240.12b-2).
Emerging growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On December 16, 2022, Synaptogenix, Inc. (the “Company”)
issued a press release announcing topline data from its National Institute of Health-sponsored Phase 2 clinical trial of Bryostatin-1
for the treatment of advanced Alzheimer's disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
by reference herein.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 16, 2022 |
Synaptogenix, Inc. |
|
|
|
|
By: |
/s/ Robert Weinstein |
|
Name: |
Robert Weinstein |
|
Title: |
Chief Financial Officer |
Synaptogenix (NASDAQ:SNPX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Synaptogenix (NASDAQ:SNPX)
Historical Stock Chart
From Jul 2023 to Jul 2024